期刊文献+

三联疗法的疗程与疗效的关系

Relationship between Treatment course and Curative Effect of Triple Therapy
暂未订购
导出
摘要 目的:探讨不同疗程的三联疗法对溃疡愈合率和幽门螺杆菌(HP)的根除率是否有影响。方法:45例经胃镜确诊的十二指肠溃疡患者,经HP检查阳性。随机分成两组进行治疗,采用埃索美拉唑,阿莫西林及克拉霉素的三联疗法。A组为埃索美拉唑每日20mg,晨起空腹服用,服6周,阿莫西林1000mg,每日2次;克拉霉素500mg,每日2次,两者均服用1周;B组埃索美拉唑用法一样,而阿莫西林及克拉霉素的疗程为2周。两组均于治疗结束后4周复查胃镜,观察溃疡愈合率,并重复HP检查,观察HP根除率。结果:A组23例,溃疡愈合21例,愈合率91.3%,HP根除20例,HP根除率为86.9%;B组22例,溃疡愈合20例,愈合率90.9%,HP根除19例,HP根除率为86.4%。两者无论是溃疡愈合率还是HP根除率均没有明显差别,在统计学中的差异无显著意义。结论:以埃索美拉唑为基础的三联疗法中,阿莫西林及克拉霉素应用的时间不同对疗效无明显影响。 Objective: To compare the effects of different triple therapy regimens on healing rates of duodenal ulcer and HP infection. Methods: A total of 45 HP-positive patients with duodenal ulcer proven by gastroscope were divided into two groups randomly, Group A: twice daily treatment with esomeprazole 20 mg for six weeks, combined with amoxieillin 1 g and elarithromycin 500 mg for 1 week; Group B: twice daily treatment with esomeprazole 20 mg for six weeks, combined with amoxicillin 1 g and clarithromycin 500 mg for 2 weeks. The ulcer healing rate, HP detection were performed 4 weeks -after the completion of therapy. Results: 45 patients completed the trial. Ulcer healing rate and HP negative rate in Group A were 91.3%(21/23) and 86.9% (20/23), respectively, and ulcer healing rate and HP negative rate in Group A were 90.9%(20/22) and 86.4%(19/ 20).There was no significant difference between two groups (p〉0.05). Conclusion: The curative effect of different triple therapy regimens based on esomeprazole is similar to each other, and the treatment course of antibiotic has no effect on healing efficacy in duodenal ulcer with HP positive.
作者 苏钢
出处 《安徽卫生职业技术学院学报》 2009年第4期26-26,28,共2页 Journal of Anhui Health Vocational & Technical College
关键词 十二指肠溃疡 幽门螺杆菌 三联疗法 疗程与疗效 Duodenal ulcer Heliwbacter Pylor TrrpleTherapy Treatment wourse and Curative Effect
  • 相关文献

参考文献3

二级参考文献17

  • 1柯美云,蓝宇,王智风,邢进宏.功能性消化不良昼夜胃内pH变化[J].临床消化病杂志,1995,7(3):97-100. 被引量:13
  • 2Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol, 1998 ; 93 (5) : 763 - 767.
  • 3Bianco A, Cagossi M, Piraccini R, et al. The nightly spontaneous alkalinization of the stomach. Riv Eur Sei Med Farmaeol,1993 ; 15(1) : 17 -27.
  • 4Robinson M. New-generation proton pump inhibitors; overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol,2001 ; 13(suppl. 1) :S43-S47.
  • 5Tytgat GNJ. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatoh 2001 ; 13 ( suppl. 1) : S29- S33.
  • 6Fouad YM, Katz PO,Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther, 1999; 13 (10) : 1467-1471.
  • 7Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther,2000; 14(9):1049-1056.
  • 8Fackler WK,Ours TM,Vaezi MF,et al. Long-term effect of H2 RA therapy on nocturnal gastric acid breakthrough. Gastroenterology, 2002 ; 122 (3) : 625 -632.
  • 9Dalenback J,Abrahamson H,Bjornson ES,et al. Human duodenogastic reflux, retroperistalsis and MMC. Am J Physiol, 1998;275 : R762-769.
  • 10Bjornson ES, Abrahamsson H. Nocturnal antral pH rises are related to duodenal phase m retroperistalsis. Dig Dis Sci, 1997;42(12) :2432-2438.

共引文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部